Molecular Devices Introduces IMAP(R) Substrate Finder for Tyrosine Kinases
14 September 2004 - 4:48AM
PR Newswire (US)
Molecular Devices Introduces IMAP(R) Substrate Finder for Tyrosine
Kinases SUNNYVALE, Calif., Sept. 13 /PRNewswire-FirstCall/ --
Molecular Devices Corporation (NASDAQ:MDCC) today announced the
introduction of its IMAP(R) Substrate Finder for Tyrosine kinases,
following the release of its initial Substrate Finder for
Serine/Threonine kinases in March. Together, they provide
substrates for the two categories of kinases that make up the human
kinome. The Substrate Finders for Tyrosine and Serine/Threonine
kinases are based on Molecular Devices' IMAP platform, which
provides advanced tools for assay development and high throughput
screening (HTS) of kinases, one of the most important target
classes in drug discovery today. The development of successful
drugs that target kinases, such as Gleevac and Iressa which
selectively target cancer cells but leave healthy cells unharmed,
is being aggressively pursued by pharmaceutical and biotechnology
companies, who are looking for quicker, easier solutions for
targeting kinase inhibitors. Kinases are important because they
play a critical role in the transmission of signals, both within
and between cells; any interference with their function can lead to
adverse effects. It is estimated that kinase malfunction
contributes to more than 400 diseases, including cancer,
inflammatory disorders like rheumatoid arthritis, diabetes,
cardiovascular disease and neurological disorders. One of the major
roadblocks facing pharmaceutical and biotechnology companies
searching for potential drug targets for these diseases is finding
a suitable substrate. The IMAP Substrate Finder accelerates the
difficult task of finding new substrates by providing a quick,
sensitive, yet inexpensive method to screen dozens of substrates in
a couple of hours versus days or weeks. "Kinase inhibitors are
important drug targets that are screened at all major
pharmaceutical companies. They represent a new generation of drugs
that target the underlying molecular processes of the cell and are
in a position to radically change the future treatments for cancer
and other diseases," stated Stephen Oldfield, Ph.D. and Vice
President of Worldwide Marketing at Molecular Devices. "Molecular
Devices' IMAP technology continues to meet the growing demands of
high throughput screening, with its stable signal, precision,
inherent flexibility and the ease in which it is incorporated into
all kinase screening. It is rapidly becoming the preferred assay to
screen for kinase activity. With the IMAP Substrate Finder, the
pace of assay development and screening for unique or proprietary
kinases is accelerated with the same ease of miniaturization and
low cost-per-well that IMAP users have come to expect." Molecular
Devices Corporation is a leading supplier of high-performance
bioanalytical measurement systems that accelerate and improve drug
discovery and other life sciences research. The Company's systems
and consumables enable pharmaceutical and biotechnology companies
to leverage advances in genomics, proteomics and combinatorial
chemistry by facilitating the high- throughput and cost-effective
identification and evaluation of drug candidates. The Company's
solutions are based on its advanced core technologies that
integrate its expertise in engineering, molecular and cell biology
and chemistry. Molecular Devices enables its customers to improve
research productivity and effectiveness, which ultimately
accelerates the complex process of discovering and developing new
drugs. This press release contains "forward-looking" statements,
including statements related to the prospects for or potential
customer use of the IMAP� Substrate Finder. Any statements
contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements.
Words such as "believes," "anticipates," "plans," "expects,"
"will," and similar expressions are intended to identify
forward-looking statements. There are a number of important factors
that could cause the results of Molecular Devices Corporation to
differ materially from those indicated by these forward-looking
statements, including, among others, risks related to the
development of new products and other risks detailed from time to
time in the Company's SEC reports, including its Annual Report on
Form 10-K for the year ended December 31, 2003, as amended, and its
Quarterly Report on Form 10-Q for the quarter ended June 30, 2004.
Molecular Devices Corporation does not undertake any obligation to
update forward-looking statements. DATASOURCE: Molecular Devices
Corporation CONTACT: Tim Harkness of Molecular Devices Corporation,
+1-408-747-3533 Web site: http://www.moleculardevices.com/
Copyright
Molecular Devices (NASDAQ:MDCC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Molecular Devices (NASDAQ:MDCC)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Molecular Devices (MM) (NASDAQ): 0 recent articles
More Molecular Devices (MM) News Articles